TYRA vs KROS vs IMVT vs CRL vs IQV

For growth investors, Keros Therapeutics, Inc.

(KROS) is the stronger pick with 67. 7% revenue growth year-over-year, versus -0. 9% for Charles River Laboratories International, Inc. (CRL). Keros Therapeutics, Inc. (KROS) offers the better valuation at 5. 1x trailing P/E, making it the more compelling value choice. Analysts rate Tyra Biosciences, Inc. (TYRA) a "Buy" — based on 7 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Keros Therapeutics, Inc.

(KROS) is the cheapest at 5. 1x versus IQVIA Holdings Inc. at 22. 8x. On forward P/E, IQVIA Holdings Inc. is actually cheaper at 14. 1x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, Immunovant, Inc.

(IMVT) delivered a total return of +62. 4%, compared to -78. 1% for Keros Therapeutics, Inc. (KROS). Over 10 years, the gap is even starker: IMVT returned +173. 6% versus KROS's -42. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Tyra Biosciences, Inc.

(TYRA) is the lower-risk stock at 0. 75β versus Charles River Laboratories International, Inc. 's 1. 52β — meaning CRL is approximately 101% more volatile than TYRA relative to the S&P 500. On balance sheet safety, Immunovant, Inc. (IMVT) carries a lower debt/equity ratio of 0% versus 2% for IQVIA Holdings Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Keros Therapeutics, Inc.

(KROS) is pulling ahead at 67. 7% versus -0. 9% for Charles River Laboratories International, Inc. (CRL). On earnings-per-share growth, the picture is similar: Keros Therapeutics, Inc. grew EPS 146. 0% year-over-year, compared to -1555. 0% for Charles River Laboratories International, Inc.. Over a 3-year CAGR, IQV leads at 4. 2% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Keros Therapeutics, Inc.

(KROS) is the more profitable company, earning 35. 7% net margin versus -3. 6% for Charles River Laboratories International, Inc. — meaning it keeps 35. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: KROS leads at 28. 9% versus 0. 0% for IMVT. At the gross margin level — before operating expenses — KROS leads at 99. 4%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, IQVIA Holdings Inc.

(IQV) trades at 14. 1x forward P/E versus 16. 4x for Charles River Laboratories International, Inc. — 2. 4x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for KROS: 781. 4% to $102. 60.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Tyra Biosciences, Inc.

(TYRA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 75)). Charles River Laboratories International, Inc. (CRL) carries a higher beta of 1. 52 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (TYRA: +26. 5%, CRL: +119. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: TYRA is a small-cap quality compounder stock; KROS is a small-cap high-growth stock; IMVT is a small-cap quality compounder stock; CRL is a small-cap quality compounder stock; IQV is a mid-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.